

Material Information (3176 MEDIGEN???????)

SEQ_NO	1	Date of announcement	2024/03/20	Time of announcement	17:32:15
Subject	Taiwan MOHW has approved a New Version of the collaborative autologous Natural Killer cell therapy project by the Company and Chi Mei Hospital, Liouying				
Date of events	2024/03/20	To which item it meets	paragraph 53		

1.Date of occurrence of the event:2024/03/20
 2.Company name:Medigen Biotechnology Corp. (Medigen)
 3.Relationship to the Company (please enter "head office" or "subsidiaries"):head office
 4.Reciprocal shareholding ratios:N/A
 5.Cause of occurrence:
 Medigen, in collaboration with Chi Mei Medical Foundation, Liouying Chi Mei Hospital (referred to as Chi Mei Hospital, Liouying), we applied to the Ministry of Health and Welfare (MOHW) received on October 25th, 2023, for a new version of the Autologous Natural Killer (Magicell-NK) cell therapy project for treating stage IV solid tumors in accordance with the regulations of the "Regulations Governing the Application of Specific Medical Examination Technique and Medical Device". On March 20th, 2024, Medigen received the approval letter from the Ministry of Health and Welfare, confirming that Medigen's Cell Processing Unit is compliant with Good Tissue Practice (GTP).

6.Countermeasures:
 The announcement was released in accordance with the approval letter of the Ministry of Health and Welfare.

7.Any other matters that need to be specified(the information disclosure also meets the requirements of Article 7, subparagraph 9 of the Securities and Exchange Act Enforcement Rules, which brings forth a significant impact on shareholders rights or the price of the securities on public companies.):
 Details on the approved items in the abovementioned Chi Mei Hospital, Liouying cell therapy project:
 (1)Type of Cell Therapy : Autologous natural killer cells (NK cells) -Magicell-NK.
 (2)Indications: Stage IV solid tumors, including brain cancer, breast cancer, lung cancer, esophageal cancer, gastric cancer, liver cancer, bile duct cancer, pancreatic cancer, prostate cancer, colorectal cancer.
 (3)Cell Processing Unit: Medigen's cell processing unit
 (4)Validity Period: From March 19th, 2024, to February 2nd, 2026